Latest in Cardiology from ACC.org

• ACC Middle East 2025: Virtual Reality Decreases Patient Anxiety During CV Procedures
  Among patients undergoing coronary angiography (CAG), using virtual reality (VR) during the procedure relieved anxiety and promoted more stable vital signs, according to research presented during the ACC Middle East 2025 Together with 16th Emirates Cardiac Society Conference, held in Dubai, UAE.
• ACC Middle East 2025: CVD Risk Increases the Longer Immigrants Live in the US
  New immigrants to the U.S. have a lower prevalence of cardiovascular disease risk factors than individuals born in the U.S., but these risk factors increase the longer they live in the U.S., a so-called "healthy immigrant effect," according to research presented during the ACC Middle East 2025 Together with 16th Emirates Cardiac Society Conference, held […]
• ASSET-IT: Early Tirofiban Increases Functional Outcomes For Noncardioembolic Stroke
  Early tirofiban significantly improved the likelihood of disability-free and functionally independent outcomes in patients with acute ischemic noncardioembolic stroke who receive thrombolysis within 4.5 hours after onset, according to results from the phase 3 ASSET-IT trial, published July 3 in NEJM.
• Federal Government Shuts Down as Telehealth Flexibilities Lapse
  The federal government shut down on Oct. 1 as lawmakers failed to reach a funding agreement. According to contingency plans from the Centers for Medicare and Medicaid Services (CMS), operations such as claims processing for Medicare, Medicaid and the Children's Health Insurance Program will continue.
• Eagle’s Eye View: Oral Semaglutide for Weight Loss; Anticoagulants for PAH; The ECDP on TR Evaluation and Management
  In this week’s View, Dr. Eagle looks at the value of oral semaglutide for weight loss. He then explores whether anticoagulants improve survival in patients with pulmonary arterial hypertension (PAH).